Atea Pharmaceuticals, Inc. (AVIR)

Price & Market Data

Price: $4.45

Daily Change: +$0.21 / 4.72%

Daily Range: $4.20 - $4.45

Market Cap: $353,719,776

Daily Volume: 411,731

Performance Metrics

1 Week: 2.13%

1 Month: -22.20%

3 Months: -8.88%

6 Months: 43.67%

1 Year: 54.48%

YTD: 21.07%

About Atea Pharmaceuticals, Inc. (AVIR)

Comprehensive financial data on Atea Pharmaceuticals, Inc. (AVIR). Trading at 4.45, it has a daily change of +$0.21 / 4.72%. Market cap: 353,719,776. Review its performance from the last week to the last year.

Company Details

Employees: 55

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Selected stocks

Reliance Global Group, Inc. (EZRA)

B&G Foods, Inc. (BGS)

Genasys Inc. (GNSS)

Sana Biotechnology, Inc. (SANA)

Inovio Pharmaceuticals, Inc. (INO)